Published in Clinical Cancer Research, a journal of the American Association for Cancer Research (AACR), preliminary results (part 1) of a two-part, first-in-human, open-label and multicenter study show that monotherapy with JNJ-64619178­—a novel, selective inhibitor of protein arginine methyltransferase 5 (PRMT5)—demonstrated manageable dose-dependent toxicity and achieved preliminary anti-tumour activity in patients with advanced malignant solid tumours or B cell non-Hodgkin lymphomas (NHL) who previously received or were ineligible for standard treatment options.

“The protein arginine methyltransferase 5 is overexpressed in several human cancers and has been shown to have oncogenic properties via epigenetic mechanisms. PRMT5 promotes the proliferation, invasion and migration of cancer cells, and therefore represents a promising target in cancer drug discovery,” observes Irene Braña, Principal Investigator of the Vall d’Hebron Institute of Oncology’s (VHIO) Head and Neck Cancer Group, CORE Phase I Investigator of VHIO’s Research Unit for Molecular Therapy of Cancer (UITM) – Caixa Research, and lead investigator of this present study in Spain.

Recent studies have shown that inhibition of PRMT5 has anti-tumour activity in subsets of cancer cell lines and animal models across various tumour types.

This study, directed by first author Manish R. Patel, Director of Drug Development, Florida Cancer Specialists/Sarah Cannon Research Institute (USA), was designed to identify the maximum tolerated dose and a recommended phase II dose for monotherapy with JNJ-64619178­, as well as evaluate the safety and preliminary efficacy of this potential new second generation epigenetic therapy in adult patients with advanced malignant solid tumours or B cell non-Hodgkin lymphomas (NHL) who previously received or were ineligible for standard treatment options.

“Based on our reported safety data and preliminary anti-tumour activity, especially in patients with ACC, we have identified the maximum tolerated dose and recommended phase II trial dose. To our knowledge, this is the first full report of a phase I study of a PRMT5 inhibitor, a target that has attracted extensive and ongoing clinical development,” says Maria Vieito, Clinical Investigator of Irene Braña’s Group and a CORE Phase I Investigator at VHIO’s UITM – CaixaResearch, Medical Oncologist at the Vall d’Hebron University Hospital (HUVH), and corresponding author of this first-in-human phase I study.

A potential second-generation epigenetic therapy 

Conducted at sites including VHIO’s Research Unit for Molecular Therapy of Cancer (UITM) – Caixa Research headed by Elena Garralda, this study enroled ninety patients with different advanced solid tumours who had received a median of three prior lines of systemic therapy, who were treated with JNJ-64619178 monotherapy.

Developed by Janssen Research and Development, JNJ-64619178­ is a potent, selective inhibitor of PRMT5, an enzyme that plays an important role in protein methylation and the development of various cancers.

The most common treatment-emergent adverse events reported were haematologic and gastrointestinal which were more frequent and acute with dosage increase.

Overall, JNJ-64619178 was well tolerated, with generally less toxicity compared with other cancer therapies targeting epigenetic mechanisms.

“Our data show preliminary anti-tumour activity, especially in patients with adenoid cystic carcinoma, which is a rare malignancy that most commonly develops in the salivary glands or other regions of the head and neck. These tumours are resistant to chemotherapy and developing effective, targeted treatments for this disease represents an unmet clinical need,” observes Vladimir Galvao, a Phase I Investigator at the UITM – Caixa Research and a co-author of this present study.  

Notably, in one patient with a rare form of pancreatic cancer who had not responded to prior therapies, JNJ-64619178 has achieved disease control since the initiation of this clinical trial four years ago.

“While preliminary results are encouraging, further development of this class of PRMT5 inhibitors as monotherapy for solid tumours will require the identification of robust biomarkers to select those patients who would most likely benefit from this type of epigenetic-based therapy. Additional preclinical studies may also identify promising combination strategies targeting PRMT5,” concludes Irene Braña, Medical Oncologist at HUVH, Vall d’Hebron Barcelona Hospital Campus.

Source: VHIO